Literature DB >> 9361616

Early adenocarcinoma in Barrett's oesophagus.

A H Hölscher1, E Bollschweiler, P M Schneider, J R Siewert.   

Abstract

BACKGROUND: The results of surgical treatment in 41 patients with early adenocarcinoma of the oesophagus were analysed retrospectively.
METHODS: The treatment of choice was transhiatal radical subtotal oesophagectomy (n = 38); in three patients with adenocarcinoma in the mid or upper thoracic portion of the oesophagus, right transthoracic en bloc oesophagectomy was performed.
RESULTS: One patient died within 30 days and another within 90 days (4.8 per cent). All tumours were resected completely. Multicentricity of adenocarcinoma in Barrett's oesophagus was detected in six cases and high-grade dysplasia in 28. Some 31 patients had infiltration of the submucosa, whereas in ten, carcinoma was limited to the mucosa. No patient with mucosal adenocarcinoma had lymph node metastases, whereas five of the 31 with submucosal infiltration showed lymph node involvement. The 5-year survival rate of the total group of 41 patients, including postoperative mortality, was 83 per cent. All ten patients with adenocarcinoma limited to the mucosa (pT1a) were alive at 5 years; of 31 with submucosal infiltration (pT1b) 79 per cent survived to 5 years (P not significant). Patients without lymph node metastasis had a 5-year survival rate of 81 per cent, compared with 50 per cent for those in the pN1 category (P not significant).
CONCLUSION: Oesophagectomy for early oesophageal adenocarcinoma is safe and leads to a favourable long-term prognosis.

Entities:  

Mesh:

Year:  1997        PMID: 9361616

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  42 in total

Review 1.  Barrett's oesophagus.

Authors:  R M Navaratnam; M C Winslet
Journal:  Postgrad Med J       Date:  1998-11       Impact factor: 2.401

2.  Guidelines for the management of oesophageal and gastric cancer.

Authors:  W H Allum; S M Griffin; A Watson; D Colin-Jones
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

Review 3.  Endoscopic management of Barrett's esophagus: advances in endoscopic techniques.

Authors:  Ali Azarm; Ismet Lukolic; Meenal Shukla; Ronald Concha-Parra; Frank Gress
Journal:  Dig Dis Sci       Date:  2012-07-04       Impact factor: 3.199

Review 4.  Esophageal resection for high-grade dysplasia and intramucosal carcinoma: When and how?

Authors:  Vani J A Konda; Mark K Ferguson
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

5.  Barrett's esophagus and the increasing role of endoluminal therapy.

Authors:  Michael S Smith; Charles J Lightdale
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

6.  Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.

Authors:  Ralf Metzger; Ute Warnecke-Eberz; Hakan Alakus; Fabian Kütting; Jan Brabender; Daniel Vallböhmer; Peter P Grimminger; Stefan P Mönig; Uta Drebber; Arnulf H Hölscher; Elfriede Bollschweiler
Journal:  J Gastrointest Surg       Date:  2011-09-29       Impact factor: 3.452

Review 7.  Endoscopic therapy for Barrett's oesophagus.

Authors:  H Barr; N Stone; B Rembacken
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 8.  Endoscopic resection of early oesophageal cancer.

Authors:  Oliver Pech; Andrea May; Thomas Rabenstein; Christian Ell
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

9.  Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial.

Authors:  A May; E Günter; F Roth; L Gossner; M Stolte; M Vieth; C Ell
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 10.  Reflux esophagitis, high-grade neoplasia, and early Barrett's carcinoma-what is the place of the Merendino procedure?

Authors:  A H Hölscher; D Vallböhmer; C Gutschow; E Bollschweiler
Journal:  Langenbecks Arch Surg       Date:  2008-11-07       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.